ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma

KATHERINE trial updates for HER2-positive breast cancer

PARP inhibitors for metastatic breast cancer

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer

Role of molecular diagnostics in prostate cancer

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history

BCMA: A new biomarker for multiple myeloma

Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma

Public policy in the fight against non-communicable diseases